Supreme Court Rejects 340B Pricing Case


Covered Entities Have No Right to Sue Manufacturers to Enforce Pricing Agreements; HHS Retains Exclusive Authority Over the Drug Discount Program

In a unanimous opinion, the Supreme Court last week held that 340B covered entities may not sue drug manufacturers for alleged violations of the 340B Pharmaceutical Pricing Agreement (PPA). Only the federal government may enforce the terms of that agreement. This decision stems a potential flood of private litigation against drug and biologics manufacturers regarding 340B and Medicaid pricing.

Justice Ginsburg authored the Court’s 8-0 opinion reversing the Ninth Circuit Court of Appeals. Justice Kagan took no part in consideration of the case.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© King & Spalding | Attorney Advertising

Written by:


King & Spalding on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.